Venus Concept Inc Stock Price, News & Analysis

Venus Concept (NASDAQ: VERO) received FDA 510(k) clearance for Venus NOVA, its next‑generation multi‑application platform for non‑invasive body, face, and skin treatments.

Key features include FlexMAX EMS (up to 100,000 contractions per session), (MP)² RF+PEMF, Advanced VariPulse™, Automatic Temperature Control, and IoT connectivity via Venus Connect. U.S. commercial availability is planned for December 2025 with global rollout in 2026. The launch is described as the first product from the company’s new R&D strategy and is supported by the Venus Jumpstart Program and financial backing from Madryn Asset Management.

Venus Concept (NASDAQ: VERO) announced that on September 30, 2025 it exchanged the full $11.48 million balance of subordinated convertible notes held by Madryn for 545,335 shares of Series Y preferred stock. Post-transaction, total debt obligations are approximately $30.1 million, a 24% reduction from $39.7 million as of December 31, 2024. Management says the exchange improves financial flexibility to support its transformation plan and return to growth.

Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has scheduled its third quarter fiscal year 2025 financial results release for November 13, 2025, before market opening.

The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Participants can join via phone using access code 13756285 or watch the live webcast on the company's investor relations website. A two-week replay will be available for those unable to attend.

Venus Concept (NASDAQ: VERO) reported Q2 2025 financial results showing total revenue of $15.7 million, down 5% year-over-year but up 15% quarter-over-quarter. U.S. revenue increased by $0.4 million (5%), driven by cash systems sales growth of 23%. The company posted a GAAP net loss of $11.7 million, improved from $19.9 million last year.

Key developments include the sale of Venus Hair business to MHG Co. Ltd for $20 million, multiple equity offerings raising $3.9 million, and debt-to-equity exchanges totaling $17.5 million. The company's gross margin declined to 60.1% from 71.5% in Q2 2024, while operating expenses increased by $1.0 million to $18.5 million.

As of June 30, 2025, Venus Concept had cash and equivalents of $4.9 million and total debt of $34.3 million, compared to $4.3 million and $39.7 million respectively at year-end 2024.

Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has scheduled its second quarter fiscal year 2025 financial results release for August 14, 2025 after market close.

The company will host a conference call at 5:00 p.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Participants can join via phone using access code 13754867 or watch the live webcast on the company's investor relations website. A two-week replay will be available for those unable to attend.

Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has announced a strategic debt-to-equity exchange transaction with Madryn Asset Management. The company exchanged $6.5 million of its subordinated convertible notes for 325,651 shares of Series Y preferred stock.

Following this transaction, Venus Concept's total debt obligations decreased to $34.3 million, representing a 14% reduction compared to the $39.7 million outstanding as of December 31, 2024. The company is currently working on completing its previously announced divestiture of the Venus Hair business while focusing on achieving sustained long-term growth and profitability.

Venus Concept (NASDAQ: VERO) has closed a registered direct offering priced at-the-market, raising $1.15 million through the sale of 434,720 shares at $2.65 per share. The company also issued unregistered short-term warrants in a concurrent private placement for up to 869,440 shares at $2.65 per share, which could generate an additional $2.3 million if fully exercised. The warrants are immediately exercisable and expire in 18 months. H.C. Wainwright & Co. served as the exclusive placement agent. The proceeds will be used for general corporate purposes. The offering includes registered common stock under Form S-3 and unregistered warrants issued under Section 4(a)(2) of the Securities Act.

Venus Concept (NASDAQ: VERO) has announced a registered direct offering of 434,720 shares at $2.65 per share, priced at-the-market under Nasdaq rules, expected to raise $1.15 million in gross proceeds. Additionally, the company will issue unregistered short-term warrants in a concurrent private placement to purchase up to 869,440 shares at $2.65 per share, potentially generating an additional $2.3 million if fully exercised. The warrants will be immediately exercisable and expire after 18 months. H.C. Wainwright & Co. is serving as the exclusive placement agent, with the offering expected to close around June 9, 2025. The company plans to use the proceeds for general corporate purposes.

Venus Concept (NASDAQ: VERO) has announced a definitive agreement to sell its Venus Hair business to Meta Healthcare Group for $20 million in cash. The transaction includes the sale of the company's hair restoration portfolio, including ARTAS and NeoGraft technologies, along with related equipment, services, and intellectual property. The deal also includes the transfer of Venus Concept's San Jose manufacturing facility. The Venus Hair business generated revenue of $12.5 million in FY2024 but used $6.7 million in cash from operations. The transaction is expected to close in Q3 2025. This strategic move aims to strengthen Venus Concept's focus on its global medical aesthetics business, potentially improving revenue growth, reducing operating expenses, and accelerating the path to profitability. Meta Healthcare Group will receive a comprehensive hair restoration portfolio and manufacturing capabilities, while Venus Concept will retain a perpetual, royalty-free, worldwide license for certain transferred patents.